Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Amid Doping Scandals, Industry Must Remain Vigilant

track

As doping in sport makes its way back into the news of the day, we must consider the consequences beyond undermining the integrity and honor of sports and competition. Doping undermines the integrity of our industry’s core mission of serving patients through drug discovery and development. Biologic products intended for use as medicines can enhance endurance, minimize recovery time, or promote muscle growth. The same medicines that can be used to help children with devastating Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

TPP and Innovation in the Bioeconomy: The Need for 12 Years of Data Protection

BIO Logo Horizontal 4C copy

A few weeks ago, BIO submitted a letter and white paper (PDF) to the U.S. Trade Representative outlining recommendations for policies to pursue with TPP negotiating partners to ensure intellectual property protection for innovative biologic products. Standards that enable biotechnology companies to protect and leverage their intellectual property are of critical importance to companies seeking breakthrough treatments and cures for patients in need worldwide. Implementing standards of protection that effectively protect innovation for biological products within the TPP region Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

These three tax tweaks can help new and small businesses create a half million jobs

shutterstock_26191726

This story from JD Harrison at the Washington Post highlights a new report from Ernst & Young that illustrates the economic impact of three tax proposals intended to help small businesses spur innovative research and development. The report indicates that the three tax revisions, if enacted together, could drive up research and development investments by more than $20 billion and create an estimated 623,000 new jobs at new and small firms. The report outlines the Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

NORD Urges Congress: Don’t Cut Orphan Drug Tax Credit

patient

This week, the National Organization of Rare Disorders (NORD) and more than 70 patient organizations sent a letter to key members of Congress in support of maintaining the Orphan Drug Tax Credit. Representing millions of American men, women and children suffering from rare diseases, the organizations voice strong support for the Orphan Drug Tax Credit (ODTC) and urge Congress to keep this critical tax credit in place as tax reform proposals are developed. According to Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Biodefense Preparedness Key for National Public Health

BARDA

Over the last decade, our nation has responded to deliberate biological attacks – the mailing of anthrax-laden letters – and severe naturally-occurring disease outbreaks including SARS and the 2009-H1N1 flu pandemic. As an industry, biotechnology can help improve our nation’s capacity to prepare and respond to natural disasters, bioterrorist attacks, and outbreaks of infectious disease. The Biomedical Advanced Research and Development Authority (BARDA) was established to support the advanced development and procurement of drugs, vaccines, Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,